Additive Anti-inflammatory Action for Aortopathy & Arteriopathy (Ulinastatin) II
Primary Purpose
Acute Aortic Syndrome, Aortic Dissection
Status
Completed
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
Ulinastatin
Saline
Sponsored by

About this trial
This is an interventional treatment trial for Acute Aortic Syndrome focused on measuring Acute Aortic Syndrome
Eligibility Criteria
Inclusion Criteria:
- The patients are conformed to 2010 ACC/AHA guidelines for the diagnosis and treatment of thoracic aortic disease (TAD) within two weeks of onset;
- Patients with acute aortic syndrome confirmed clinically and radiologically and planning to undergo emergency aortic arch replacement surgery were enrolled.
- The patients' age between 15 ~85 years old.
- Agree to participate in the study and sign the informed consent.
Exclusion Criteria:
- Patients allergic to Ulinastatin;
- Patients with active or acute liver disease;
- Patients with chronic kidney disease;
- Lactating women and pregnant women;
- Patients with mental diseases, drug and alcohol dependence;
- Refuse to participate in this study and refuse to sign the informed consent.
Sites / Locations
- The first affiliated hospital of nanjing medical university
- Beijing Anzhen Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Ulinastatin
Saline
Arm Description
Ulinastatin 10 0000 Units is taken intravenously three times a day.
Same saline dose as ulinastatin is taken intravenously three times a day.
Outcomes
Primary Outcome Measures
Oxygenation index
Oxygenation index is calculated as PaO2/FiO2.
Secondary Outcome Measures
Mortality
Death from any cause
Full Information
NCT ID
NCT04711889
First Posted
January 13, 2021
Last Updated
February 1, 2023
Sponsor
Nanjing Medical University
Collaborators
Beijing Anzhen Hospital
1. Study Identification
Unique Protocol Identification Number
NCT04711889
Brief Title
Additive Anti-inflammatory Action for Aortopathy & Arteriopathy (Ulinastatin) II
Official Title
Effects of Ulinastatin on Inflammatory Response for Acute Aortic Syndrome Patients
Study Type
Interventional
2. Study Status
Record Verification Date
February 2023
Overall Recruitment Status
Completed
Study Start Date
January 1, 2021 (Actual)
Primary Completion Date
June 30, 2022 (Actual)
Study Completion Date
June 30, 2022 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Nanjing Medical University
Collaborators
Beijing Anzhen Hospital
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Acute Aortic Syndrome (AAS) is a common feature of acute aortic wall events, including aortic dissection, intramural hematoma, aortic ulceration and aortic trauma, and occurs in up to 35 cases per 100,000 cases per year between the ages of 65 and 75 years. Ulinastatin has antiinflammatory activity and suppresses the infiltration of neutrophils and the release of elastase and chemical mediators from neutrophils. Recent studies have shown that ulinastatin may be cytoprotective against ischemia-reperfusion injury in the liver, kidney, heart, and lung. The authors aim to examine the association between decreased release of inflammatory response to urinary trypsin inhibitor treatment and decreased myocardial and lung injury after acute aortic syndrome surgery.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acute Aortic Syndrome, Aortic Dissection
Keywords
Acute Aortic Syndrome
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
220 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Ulinastatin
Arm Type
Experimental
Arm Description
Ulinastatin 10 0000 Units is taken intravenously three times a day.
Arm Title
Saline
Arm Type
Placebo Comparator
Arm Description
Same saline dose as ulinastatin is taken intravenously three times a day.
Intervention Type
Drug
Intervention Name(s)
Ulinastatin
Intervention Description
Ulinastatin is taken three times a day.
Intervention Type
Drug
Intervention Name(s)
Saline
Intervention Description
Saline is taken three times a day.
Primary Outcome Measure Information:
Title
Oxygenation index
Description
Oxygenation index is calculated as PaO2/FiO2.
Time Frame
3 days after surgery
Secondary Outcome Measure Information:
Title
Mortality
Description
Death from any cause
Time Frame
30 days after surgery
10. Eligibility
Sex
All
Minimum Age & Unit of Time
15 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
The patients are conformed to 2010 ACC/AHA guidelines for the diagnosis and treatment of thoracic aortic disease (TAD) within two weeks of onset;
Patients with acute aortic syndrome confirmed clinically and radiologically and planning to undergo emergency aortic arch replacement surgery were enrolled.
The patients' age between 15 ~85 years old.
Agree to participate in the study and sign the informed consent.
Exclusion Criteria:
Patients allergic to Ulinastatin;
Patients with active or acute liver disease;
Patients with chronic kidney disease;
Lactating women and pregnant women;
Patients with mental diseases, drug and alcohol dependence;
Refuse to participate in this study and refuse to sign the informed consent.
Facility Information:
Facility Name
The first affiliated hospital of nanjing medical university
City
Nanjing
State/Province
Jiangsu
ZIP/Postal Code
210029
Country
China
Facility Name
Beijing Anzhen Hospital
City
Beijing
Country
China
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Learn more about this trial
Additive Anti-inflammatory Action for Aortopathy & Arteriopathy (Ulinastatin) II
We'll reach out to this number within 24 hrs